Outcomes of intraluminal ripcord removal from Paul glaucoma implants.

ABSTRACT:

Background/aims

To investigate the efficacy and safety of intraluminal ripcord suture removal (ROS) from the Paul glaucoma implant (PGI).

Methods

A retrospective cohort study involving all PGI ripcord removal cases at a single centre between 1 January 2018 and 1 November 2023. The primary outcome was defined as a ≥20% reduction in intraocular pressure (IOP), or a decrease in IOP-lowering medications, at 3 months post-ROS.

Results

145 eyes of 131 patients were included. The mean interval between PGI implantation and ROS was 181.9±131.4 days. 70.3% of eyes met the primary endpoint of success, with second tubes and infero-nasal tube placement significantly associated with reduced success (p<0.05). Compared with the pre-ROS mean IOP (19.5±6.7 mm Hg), the post-ROS IOPs at

SUBMITTER: Mendel L 

PROVIDER: S-EPMC12573402 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature